Butasiv Tablet (Sustained Release) 50 mg
Butasiv Tablet (Sustained Release) 50 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Butasiv Tablet (Sustained Release) 50 mg |
| Generic | Butamirate Citrate |
| Weight | 50 mg |
| Type | Tablet (Sustained Release) |
| Therapeutic Class | Cough suppressant |
| Manufacturer | Jenphar Bangladesh Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Butasiv Tablet (Sustained Release) 50 mg is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Butasiv Tablet (Sustained Release) 50 mg is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.Dosage
Butasiv Tablet (Sustained Release) 50 mg dosage
Use in adult: Butasiv Tablet (Sustained Release) 50 mg 50 mg tablet: 2-3 tablets daily. Butasiv Tablet (Sustained Release) 50 mg syrup: 15 ml 4 times daily. Use in children & adolescents:Butasiv Tablet (Sustained Release) 50 mg 50 mg tablet: Adolescent over 12 years old: 1-2 tablets daily. Butasiv Tablet (Sustained Release) 50 mg syrup: Children (3-6 yrs): 5 ml 3 times daily. Children (6-12 yrs): 10 ml 3 times daily. Adolescent: 15 ml 3 times daily. Butasiv Tablet (Sustained Release) 50 mg pediatric drops: Children ( 2 months- 1 yrs): 0.50 ml 4 times daily. Children (1-3 yrs): 0.75 ml 4 times daily.Side Effects
Tolerance of Butasiv Tablet (Sustained Release) 50 mg is good.Adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal.Precaution
Butasiv Tablet (Sustained Release) 50 mg suppresses the cough reflex and therefore the concomitant use with expectorants should be avoided, since it may lead to mucus retention in the airways, which increases the risk of bronchospasm and respiratory infections. If the cough persists for more than 7 days (more than 3 days in children younger than12 years of age) doctor must be consulted.Interaction
Concomitant use with expectorants should be avoided.Pregnancy & Breastfeeding use
Butasiv Tablet (Sustained Release) 50 mg should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butasiv Tablet (Sustained Release) 50 mg administration during breast feeding should be carefully weighed against the risks.Contraindication
Hypersensitivity to the active ingredient.Acute Overdose
Accidental overdose with Butasiv Tablet (Sustained Release) 50 mg can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.Storage Condition
Keep away from light and moisture, store below 30°C. Keep all the medicines out of the reach of children.Innovators Monograph
You find simplified version here Butasiv Tablet (Sustained Release) 50 mg
